JP2019509288A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509288A5
JP2019509288A5 JP2018547294A JP2018547294A JP2019509288A5 JP 2019509288 A5 JP2019509288 A5 JP 2019509288A5 JP 2018547294 A JP2018547294 A JP 2018547294A JP 2018547294 A JP2018547294 A JP 2018547294A JP 2019509288 A5 JP2019509288 A5 JP 2019509288A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
hydrogen
aryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018547294A
Other languages
English (en)
Japanese (ja)
Other versions
JP6860585B2 (ja
JP2019509288A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021559 external-priority patent/WO2017156262A1/en
Publication of JP2019509288A publication Critical patent/JP2019509288A/ja
Publication of JP2019509288A5 publication Critical patent/JP2019509288A5/ja
Application granted granted Critical
Publication of JP6860585B2 publication Critical patent/JP6860585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018547294A 2016-03-09 2017-03-09 非環状抗ウイルス 優先出願の参照による組み込み Expired - Fee Related JP6860585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662305723P 2016-03-09 2016-03-09
US62/305,723 2016-03-09
PCT/US2017/021559 WO2017156262A1 (en) 2016-03-09 2017-03-09 Acyclic antivirals

Publications (3)

Publication Number Publication Date
JP2019509288A JP2019509288A (ja) 2019-04-04
JP2019509288A5 true JP2019509288A5 (enExample) 2020-04-16
JP6860585B2 JP6860585B2 (ja) 2021-04-14

Family

ID=58361178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018547294A Expired - Fee Related JP6860585B2 (ja) 2016-03-09 2017-03-09 非環状抗ウイルス 優先出願の参照による組み込み

Country Status (7)

Country Link
US (2) US10745427B2 (enExample)
EP (1) EP3426642A4 (enExample)
JP (1) JP6860585B2 (enExample)
CN (1) CN109071467B (enExample)
AU (1) AU2017231824B2 (enExample)
TW (1) TWI740910B (enExample)
WO (1) WO2017156262A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684067A (zh) 2012-12-21 2020-01-14 艾丽奥斯生物制药有限公司 取代的核苷和核苷酸
JP6860585B2 (ja) 2016-03-09 2021-04-14 ヤンセン バイオファーマ インク. 非環状抗ウイルス 優先出願の参照による組み込み
WO2018055071A1 (en) * 2016-09-23 2018-03-29 Katholieke Universiteit Leuven Prodrugs of fluorinated acyclic nucleoside phosphonates
AU2019209594B2 (en) * 2018-01-19 2021-09-23 Gilead Sciences, Inc. Metabolites of bictegravir
US20220048912A1 (en) 2018-12-12 2022-02-17 Janssen Biopharma, Inc. Cyclobutyl nucleoside analogs as anti-virals
MX2021006993A (es) 2018-12-12 2021-10-22 Janssen Biopharma Inc Analogos de nucleosidos de ciclopentilo como antivirales.
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
CN114901657A (zh) 2019-10-17 2022-08-12 人工智能生物制药公司 抗病毒和肝靶向药物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (en) 2020-02-18 2025-09-17 Gilead Sciences, Inc. Antiviral compounds
CN111909153B (zh) * 2020-04-16 2021-11-19 山东鲁西药业有限公司 7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的合成工艺
WO2021243658A1 (en) * 2020-06-04 2021-12-09 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
WO2022081823A1 (en) * 2020-10-14 2022-04-21 Temple University -Of The Commonwealth System Of Higher Education Pharmacologic approach for suppression of coronaviruses
KR102923359B1 (ko) 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3490262T1 (de) * 1983-05-24 1985-11-28 Sri International, Menlo Park, Calif. Antivirus-Mittel
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5532225A (en) * 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US5877166A (en) * 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
DE19912636A1 (de) * 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
DZ3487A1 (fr) 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
EA200400690A1 (ru) * 2001-11-14 2005-06-30 Байокрист Фармасьютикалз, Инк. Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
FR2850653A1 (fr) * 2003-02-04 2004-08-06 Univ Pasteur Derives de pyrazolotriazine, procede de preparation et utilisations
CN101381379A (zh) * 2003-04-25 2009-03-11 吉里德科学公司 激酶抑制性膦酸酯类似物
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ, インコーポレイテッド キナーゼインヒビターホスホネート抱合体
US20050080053A1 (en) * 2003-08-29 2005-04-14 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
CN1921867B (zh) * 2004-02-17 2010-05-05 株式会社Lg生命科学 用于治疗hiv感染的膦酸核苷衍生物
PL216369B1 (pl) * 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
SG177974A1 (en) * 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
CN101066981B (zh) * 2007-05-25 2011-10-05 中国科学院上海药物研究所 非环核苷膦酸酯类化合物及其组合物、制备方法和用途
WO2009117157A1 (en) 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
AU2009240630B2 (en) 2008-04-23 2013-07-18 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
BR122021021135B1 (pt) * 2009-09-21 2022-08-30 Gilead Sciences, Inc Compostos análogos de 2-flúor substituído carba-nucleosídeo, composição farmacêutica e uso dos compostos análogos de 2´-flúoro substituído carbonucleosídeo
ES2581065T3 (es) 2012-02-23 2016-08-31 Bayer Intellectual Property Gmbh Benzotienil-pirrolotriazinas sustituidas y usos de las mismas
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
JP6338402B2 (ja) 2014-03-07 2018-06-06 日東電工株式会社 樹脂フィルム
JP6860585B2 (ja) 2016-03-09 2021-04-14 ヤンセン バイオファーマ インク. 非環状抗ウイルス 優先出願の参照による組み込み

Similar Documents

Publication Publication Date Title
JP2019509288A5 (enExample)
JP2020172511A5 (enExample)
JP2016529324A5 (enExample)
JP2017523225A5 (enExample)
JP2010514768A5 (enExample)
JP2014518546A5 (enExample)
JP2013537907A5 (enExample)
JP2013503862A5 (enExample)
PH12018550148A1 (en) Hepatitis b antiviral agents
JP2019514426A5 (enExample)
RU2016138735A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
JP2018510159A5 (enExample)
JP2018520352A5 (enExample)
JP2014500265A5 (enExample)
JP2009538348A5 (enExample)
JP2013504576A5 (enExample)
EA202090514A1 (ru) Противовирусное средство против гепатита в
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
JP2010521485A5 (enExample)
JP2016506959A5 (enExample)
EA201201031A1 (ru) Ингибиторы вируса гепатита с
JP2015531789A5 (enExample)
JP2015518001A5 (enExample)
JP2017526677A5 (enExample)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич